Currently, the majority of patients with persistent asthma
successfully control their disease through the use of more-conventional inhaled
agents. However, there remains a subset of patients whose disease remains
uncontrolled despite full compliance with a multi-drug regimen that includes
medium- or high-dose inhaled corticosteroid plus a long-acting beta2
agonist or unacceptable doses of oral corticosteroids. These patients have
severe, refractory asthma, and to date, their only treatment option has been Xolair
(Genentech/Novartis’s omalizumab), an IgE inhibitor launched in the United
States in 2003. In the late-stage pipeline for severe asthma are three novel
biologic agents and Spiriva (Boehringer Ingelheim/Pfizer’s tiotropium), which
we expect to help fulfill the unmet need in this population. The entrance of
these therapies will lead to the development of a more complex marketplace for
severe, refractory disease, one that will require physicians and payers alike
to make key decisions about which treatments to prescribe or reimburse over
others. In this report, which is based on our survey of 100 pulmonologists and
28 managed care organization (MCO) pharmacy or medical directors, we examine
the dynamics that will limit or promote market access of new therapies for
severe, refractory asthma.
This U.S. Physician & Payer Forum investigates payer and physician dynamics that affect prescribing practices for therapies for severe, refractory asthma in the United States. The report is based on a survey of 100 pulmonologists and 28 pharmacy/medical directors at MCOs that offer commercial health insurance. We analyze current physician and payer insights and practices; their perceptions of biologics and Spiriva in the pipeline; the likely uptake of emerging therapies for severe, refractory asthma; and formulary decision making for current and emerging agents, including Genentech/Novartis’s omalizumab (Xolair), Cephalon/Teva’s reslizumab (Cinquil), GlaxoSmithKline’s mepolizumab (Bosatria), Genentech’s lebrikizumab, and Boehringer Ingelheim/Pfizer’s tiotropium (Spiriva).
Markets covered: United States.
Primary research: Online survey of 100 pulmonologists and 28 MCO pharmacy or medical directors.
Population segments: Patients with severe, refractory asthma.